Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 1;32(2):70-75.
doi: 10.1089/ped.2018.0967. Epub 2019 Jun 17.

Subcutaneous Immunoglobulin Twenty Percent Every Two Weeks in Pediatric Patients with Primary Immunodeficiencies: Subcohort Analysis of the IBIS Study

Clementina Canessa  1 , Vera Gallo  2 , Claudio Pignata  2 , Antonino Trizzino  3 , Simona Graziani  4 , Baldassarre Martire  5 , Viviana Moschese  4 , Valentina Palladino  6 , Giorgio Maria Boggia  7 , Andrea Matucci  8 , Antonio Pecoraro  9 , Giuseppe Spadaro  9 , Alessandra Vultaggio  8 , Chiara Azzari  1
Affiliations

Subcutaneous Immunoglobulin Twenty Percent Every Two Weeks in Pediatric Patients with Primary Immunodeficiencies: Subcohort Analysis of the IBIS Study

Clementina Canessa et al. Pediatr Allergy Immunol Pulmonol. .

Abstract

Background: Subcutaneous immunoglobulin G (SCIG) may be a better option than intravenous immunoglobulin G (IVIG) for patients with primary immunodeficiencies (PID) due to reduced systemic and serious adverse reactions and easier administration. The Infusione Bimensile di Immunoglobuline Sottocute (IBIS) study investigated the effects of Hizentra®, a 20%-concentrated SCIG, administered biweekly in patients with PID. This subanalysis aimed to evaluate clinical and laboratory outcomes in the IBIS pediatric subcohort. Methods: Thirteen children with PID were observed for 12 months retrospectively (with previous IVIG/SCIG) and prospectively with biweekly Hizentra. Results: Mean ± standard deviation serum IG levels during the retrospective (833.8 ± 175.7 mg/dL) and the prospective (842.0 ± 188.0 mg/dL) phases were comparable; there were also no differences in the number of infections. Conclusions: Biweekly Hizentra is a noninferior option with respect to previous IVIG/SCIG-based treatment.

Keywords: children; immunoglobulin; pediatric; primary immunodeficiencies; subcutaneous.

PubMed Disclaimer

Conflict of interest statement

G.M.B. is an employee of CSL Behring. C.C., V.G., C.P., A.T., S.G., B.M., V.M., V.P., A.M., A.P., G.S., A.V., and C.A. declare no conflicts of interest.

Figures

<b>FIG. 1.</b>
FIG. 1.
Design of the IBIS study. IBIS, Infusione Bimensile di Immunoglobuline Sottocute; IVIG, intravenous immunoglobulin G; SCIG, subcutaneous immunoglobulin; T, time.
<b>FIG. 2.</b>
FIG. 2.
Serum IgG trough levels during the retrospective and prospective phases when patients received subcutaneous immunoglobulins. FPFV, first patient first visit; IgG, immunoglobulin G; LPLV, last patient last visit.
<b>FIG. 3.</b>
FIG. 3.
Comparison of (A) IgG levels, (B) number of infections, (C) rate of infections, (D) antibiotic therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 2000; 343:1313–1324 - PubMed
    1. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am 2008; 28:413–437 - PMC - PubMed
    1. Bousfiha A, Jeddane L, Picard C, et al. . The 2017 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol 2018; 38:129–143 - PMC - PubMed
    1. Radinsky S, Bonagura VR. Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. J Allergy Clin Immunol 2003; 112:630–633 - PubMed
    1. Gardulf A, Nicolay U, Asensio O, et al. . Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-a prospective, multi-national study. J Clin Immunol 2006; 26:177–185 - PubMed

LinkOut - more resources